WEBINAR: JUNE 26 | 11AM ET/8 AM
PT Biosimilar legislation passed in 2010 guaranteed 12 years of patent
protection to biotechs from biosimilar competition. But passing the law was the
easy part. As FDA hashes out regulations to implement the law, we help CMOs
understand the significance of the legislation to their businesses and how the
new legislation may help, or hurt, contract manufacturing for biologics.
Register Now! Sign up for our FREE newsletter for more news like this sent to
your inbox! Roche comes to the game in fairly different position. The Swiss
drug giant, which currently lacks a big cardio business, seeks its first
multibillion-dollar seller in this category. In May the drugmaker wrote off its
experimental dalcetrapib after the drug for increasing good cholesterol bombed
in a late-stage study. As Bloomberg reports, Roche has kept details about its
PCSK9 drug from U.S.
unit Genentech under wraps because of the intense competition in the field. Yet
that will rapidly change as Roche unveils data on the program and builds its
case with docs to enroll their patients in its studies. Behind Roche's and
Sanofi's PCSK9 programs are several more. Amgen ($AMGN) and Pfizer are in
mid-stage studies with their own candidates aimed at the hot target. Also,
Bristol-Myers Squibb ($BMY), Merck ($MRK) and Alnylam ($ALNY) have research
underway in the field. "These drugs allow us to go where no one has gone
before," Steven Nissen, chairman of the Department of Cardiovascular
Medicine at the Cleveland Clinic in Ohio ,
said in an interview with Bloomberg. "There's a tremendous amount of
interest among a broad range of makers of pharmaceuticals to get
involved."
No comments:
Post a Comment